Thompson has over 25 years of executive, commercial and marketing experience in the biotech and pharmaceutical industry. Prior to Neurana, he served as president and CEO of Anthera Pharmaceuticals, Inc. Previously, Thompson served as COO of Tetraphase Pharmaceuticals, Inc., where he oversaw the development and implementation of the marketing, access and reimbursement and sales strategy, as well as business development and commercial manufacturing for the company.
Prior to Tetraphase, he was CCO for Trius Therapeutics, Inc., and earlier in his career, Thompson served in various commercial and marketing roles of increasing responsibility at Pfizer Inc. and Merck and Co, Inc. He holds a Bachelor of Commerce degree from McMaster University and an M.B.A. from the University of Notre Dame.
Foster has over 25 years of progressive clinical development and project management experience including international management of over 50 clinical drug trials from first-in-human Phase 1 trials to large, complex global Phase 3 trials.
She was most recently executive vice president, Development Operations at Sanifit, Inc. and has held senior clinical and operational positions at Orexigen Therapeutics, Inc., PRA International, BioVascular, Inc., La Jolla Pharmaceutical Co., PAREXEL Corp., and Quintiles, Inc.
Neurana recently completed a USD60 m series A financing to further develop tolperisone, a novel, patented skeletal muscle relaxant for the treatment of acute, painful muscle spasms without sedation.
The company is preparing to commence a Phase 2 dose ranging clinical trial to further demonstrate the safety and efficacy of tolperisone in subjects with acute, painful muscle spasms of the neck and back.
Neurana Pharmaceuticals is a private company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back and spasticity. The company is currently beginning a Phase 2 clinical trial on the company's lead compound tolperisone.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer